Dopamine Signaling Controls Pathological Tau
Brian Kraemer, PhD VA Puget Sound Health Care System (VAPSHCS)
A number of neurodegenerative disorders feature tau deposits, including Alzheimer’s disease. These abnormal aggregations of tau protein can cause age-dependent neurodegeneration. We have identified a class of drugs that prevent abnormal tau formation in animal models of Alzheimer’s disease. The goal of this project is to understand how these experimental drugs prevent abnormal tau so that we can develop these drugs further, ultimately setting the stage for clinical trials in Alzheimer’s patients.